EA200800996A1 - Способ получения т-клеточной популяции - Google Patents

Способ получения т-клеточной популяции

Info

Publication number
EA200800996A1
EA200800996A1 EA200800996A EA200800996A EA200800996A1 EA 200800996 A1 EA200800996 A1 EA 200800996A1 EA 200800996 A EA200800996 A EA 200800996A EA 200800996 A EA200800996 A EA 200800996A EA 200800996 A1 EA200800996 A1 EA 200800996A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cell population
obtaining
cell
expresses
cd62l
Prior art date
Application number
EA200800996A
Other languages
English (en)
Other versions
EA016168B1 (ru
Inventor
Тацудзи Эноки
Акико Като
Нобуко Мураки
Мицуко Идено
Такахиро Маруи
Хироаки Сагава
Икуносин Като
Original Assignee
Такара Био Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Такара Био Инк. filed Critical Такара Био Инк.
Publication of EA200800996A1 publication Critical patent/EA200800996A1/ru
Publication of EA016168B1 publication Critical patent/EA016168B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46434—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46449—Melanoma antigens
    • A61K39/464491—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/58—Adhesion molecules, e.g. ICAM, VCAM, CD18 (ligand), CD11 (ligand), CD49 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C12N2533/52—Fibronectin; Laminin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Способ получения Т-клеточной популяции, в котором Т-клеточная популяция экспрессирует CD45RA и экспрессирует по меньшей мере один маркер, выбранный из группы, состоящей из CD62L, CCR7, CD27 и CD28, отличающийся тем, что способ включает в себя стадию культивирования клеточной популяции, содержащей Т-клетку, в присутствии фибронектина, его фрагмента или их смеси.
EA200800996A 2005-09-30 2006-09-27 Способ получения т-клеточной популяции и ее применение EA016168B1 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2005288983 2005-09-30
JP2006102103 2006-04-03
JP2006196950 2006-07-19
JP2006241773 2006-09-06
PCT/JP2006/319105 WO2007040105A1 (ja) 2005-09-30 2006-09-27 Ｔ細胞集団の製造方法

Publications (2)

Publication Number Publication Date
EA200800996A1 true EA200800996A1 (ru) 2008-08-29
EA016168B1 EA016168B1 (ru) 2012-02-28

Family

ID=37906148

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200800996A EA016168B1 (ru) 2005-09-30 2006-09-27 Способ получения т-клеточной популяции и ее применение

Country Status (11)

Country Link
US (1) US20100068192A1 (ru)
EP (1) EP1939278A4 (ru)
JP (1) JP5156382B2 (ru)
KR (1) KR101408565B1 (ru)
CN (1) CN101400785B (ru)
AU (1) AU2006298188B2 (ru)
CA (1) CA2623735A1 (ru)
EA (1) EA016168B1 (ru)
HK (1) HK1130509A1 (ru)
TW (1) TW200741001A (ru)
WO (1) WO2007040105A1 (ru)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007142300A1 (ja) * 2006-06-09 2007-12-13 Takara Bio Inc. リンパ球の製造方法
TW200908988A (en) * 2007-05-11 2009-03-01 Takara Bio Inc Therapeutic agent for cancer
WO2008143255A1 (ja) * 2007-05-22 2008-11-27 Takara Bio Inc. 細胞集団の製造方法
EP2155873B1 (en) 2007-05-23 2016-11-09 Sangamo BioSciences, Inc. Methods and compositions for increased transgene expression
EP2267118A4 (en) * 2008-03-27 2013-08-28 Takara Bio Inc METHOD FOR PRODUCING A TRANSFICED CELL
CN101831434B (zh) * 2009-07-27 2012-05-09 浙江大学 抗人cd45ra鼠免疫球蛋白可变区基因及用途
CN101706507B (zh) * 2009-07-27 2013-05-01 浙江大学 用异硫氰酸荧光素标记的抗人cd45ra单抗的应用
EP2476752A4 (en) * 2009-09-11 2013-04-03 Takara Bio Inc PROCESS FOR THE PRODUCTION OF NATURAL KILLER CELLS
MX2014010183A (es) 2012-02-22 2015-03-20 Univ Pennsylvania Composiciones y metodos para generar una poblacion persistente de celulas t utiles para el tratamiento de cancer.
CN108498532B (zh) 2012-05-09 2021-07-23 坎泰克斯制药股份有限公司 骨髓抑制的治疗
ES2831315T3 (es) * 2013-04-03 2021-06-08 Memorial Sloan Kettering Cancer Center Generación efectiva de células T dirigidas al tumor derivadas de células madre pluripotentes
US10052346B2 (en) 2015-02-17 2018-08-21 Cantex Pharmaceuticals, Inc. Treatment of myelodysplastic syndromes with 2-O and,or 3-O desulfated heparinoids
EP3258940A1 (en) * 2015-02-17 2017-12-27 Cantex Pharmaceuticals, Inc. Adoptive cell transfer methods
EP3091032A1 (en) * 2015-05-08 2016-11-09 Miltenyi Biotec GmbH Humanized antibody or fragment thereof specific for cd3
MA45488A (fr) * 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés, kits et appareil de culture de cellules
CN115094036A (zh) 2016-04-08 2022-09-23 爱默蕾大学 使用基于细胞的疗法治疗癌症和传染病的方法
WO2017214939A1 (zh) * 2016-06-16 2017-12-21 毛侃琅 提升 ccr7 基因表达水平的慢病毒表达载体及其应用
JP7382603B2 (ja) * 2018-08-10 2023-11-17 国立大学法人京都大学 Ｃｄ３陽性細胞の製造方法
CA3110706A1 (en) * 2018-09-19 2020-03-26 FUJIFILM Cellular Dynamics, Inc. Protein l for activation and expansion of chimeric antigen receptor-modified immune cells
WO2020102701A1 (en) * 2018-11-16 2020-05-22 Rapa Therapeutics, Llc Methods for the manufacture of th1/tc1 phenotype t cells
WO2023155009A1 (en) * 2022-02-16 2023-08-24 Stemcell Technologies Canada Inc. Compositions and methods for expanding lymphocytes

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2561131B2 (ja) * 1988-06-30 1996-12-04 寳酒造株式会社 細胞接着活性ポリペプチド
US5198423A (en) 1989-05-26 1993-03-30 Takara Shuzo Co., Ltd. Functional polypeptide containing a cell binding domain and a heparin binding domain of fibronectin
US5188959A (en) * 1989-09-28 1993-02-23 Trustees Of Tufts College Extracellular matrix protein adherent t cells
JP3104178B2 (ja) 1990-03-30 2000-10-30 寶酒造株式会社 機能性ポリペプチド
JP2729712B2 (ja) 1991-04-23 1998-03-18 寳酒造株式会社 機能性ポリペプチド
US6821778B1 (en) * 1993-12-01 2004-11-23 The Board Of Trustees Of Leland Stanford Junior University Methods for using dendritic cells to activate gamma/delta-T cell receptor-positive T cells
DE4412794A1 (de) * 1994-04-14 1995-12-14 Univ Ludwigs Albert Verfahren zur Herstellung von dendritischen Zellen, so erhaltene Zellen und Behälter zur Durchführung dieses Verfahrens
US5827642A (en) * 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US7067318B2 (en) * 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6692964B1 (en) * 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
EP0824594B1 (en) * 1995-05-04 2005-04-06 The United States of America as Representend by The Secretary of the Navy Improved methods for transfecting t cells
EP0870839B1 (en) * 1995-11-13 2006-05-10 Takara Bio Inc. Method for gene introduction into target cells by retrovirus
US6734014B1 (en) * 1996-02-08 2004-05-11 The United States Of America As Represented By The Department Of Health And Human Services Methods and compositions for transforming dendritic cells and activating T cells
DE69739951D1 (de) * 1996-03-04 2010-09-16 Calyx Bio Ventures Inc Modifizierte schnellvermehrungsmethode ('modified-rem') zur in vitro vermehrung von t-lymphozyten
TWI239352B (en) * 1997-07-23 2005-09-11 Takara Bio Inc Gene transfer method with the use of serum-free medium
CA2340086A1 (en) 1998-08-11 2000-02-24 The United States Of America, Represented By Department Of Health And Hu Man Services A method of transducing mammalian cells, and products related thereto
ATE376840T1 (de) * 1999-03-23 2007-11-15 Takara Bio Inc Gentherapeutika
KR20020010206A (ko) * 2000-07-27 2002-02-04 이시우 인터루킨 12와 보조활성인자 ｂ7.1 유전자를 함유하는ｄｎａ 벡터 및 이벡터가 도입된 항암 세포백신
EP1312670A4 (en) * 2000-08-16 2005-11-30 Takara Bio Inc METHOD FOR THE EXTENSIVE CULTURE OF ANTIGEN-SPECIFIC CYTOTOXIC T CELLS
JP2004528042A (ja) * 2001-06-01 2004-09-16 エクサイト セラピーズ， インコーポレイテッド Ｔ細胞誘導性組織修復および再生
WO2003016511A1 (en) * 2001-08-15 2003-02-27 Takara Bio Inc. Method of extended culture for antigen-specific cytotoxic t lumphocytes
US7745140B2 (en) * 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
KR100895231B1 (ko) * 2002-03-25 2009-05-04 다카라 바이오 가부시키가이샤 세포상해성 림프구의 제조방법
AU2003254950A1 (en) * 2002-08-26 2004-03-11 Kirin Beer Kabushiki Kaisha Peptides and drugs containing the same
EP1666589B1 (en) * 2003-08-22 2010-02-17 Takara Bio Inc. Process for producing cytotoxic lymphocytes
US20080227504A1 (en) * 2007-03-15 2008-09-18 Shih-Yang Chan Ceramic casing device for mobile handset

Also Published As

Publication number Publication date
AU2006298188B2 (en) 2012-03-15
HK1130509A1 (en) 2009-12-31
US20100068192A1 (en) 2010-03-18
EP1939278A4 (en) 2009-06-03
CN101400785A (zh) 2009-04-01
EP1939278A1 (en) 2008-07-02
AU2006298188A1 (en) 2007-04-12
JPWO2007040105A1 (ja) 2009-04-16
CN101400785B (zh) 2013-09-25
EA016168B1 (ru) 2012-02-28
CA2623735A1 (en) 2007-04-12
WO2007040105A1 (ja) 2007-04-12
KR20080056266A (ko) 2008-06-20
TW200741001A (en) 2007-11-01
JP5156382B2 (ja) 2013-03-06
KR101408565B1 (ko) 2014-06-17

Similar Documents

Publication Publication Date Title
EA200800996A1 (ru) Способ получения т-клеточной популяции
TW200741000A (en) Method of producing lymphocytes
SG152273A1 (en) Pdx1 expressing endoderm
WO2005021728A3 (en) Enriched pancreatic stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for these populations
MX2008011838A (es) Propagacion de celulas primarias.
MX2008014692A (es) Metodo de cultivo para obtener una poblacion clonal de celulas b especificas de antigeno.
NZ595786A (en) Placental stem cell populations
WO2004044142A3 (en) Mesenchymal stem cells and methods of use thereof
DE602005021379D1 (de) System und verfahren zur produktion von antikörpern in der pflanzenzellkultur
WO2007008722A3 (en) Method for the isolation of rna from biological sources
DE602004025805D1 (de) Verfahren zur herstellung von antikörpern
WO2006113881A3 (en) Method of using stroma cells from cord blood to expand and engraft nucleated cells from cord blood
WO2006108882A8 (en) In vitro production of a cell population using feeder cells
ATE437906T1 (de) Verfahren zur herstellung von pfropfpolymerisaten
ATE505535T1 (de) Verfahren zur herstellung stabiler b-lymphozyten
TWI315740B (ru)
AU2019268061A1 (en) Placental stem cell populations
WO2008095165A3 (en) Cell co-culture systems and uses thereof
WO2005103229A3 (en) Transgenomic mitochondria, transmitochondrial cells and organisms, and methods of making and using
MXPA06012987A (es) Epitopos inductores de muerte de celulas t.
WO2008111430A1 (ja) γδＴ細胞集団の製造方法
EP2377922A3 (en) PDX1 expressing endoderm
ATE530590T1 (de) Verfahren zur herstellung von polyesterolen
WO2006047426A3 (en) Compositions, methods and systems for preparation of a stem cell-enriched cell population
WO2005028621A3 (en) Assays with primary cells

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU